510 related articles for article (PubMed ID: 32822738)
1. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
[TBL] [Abstract][Full Text] [Related]
2. Glycogen Synthase Kinase-3β (GSK-3β) Inhibition Enhances Dendritic Cell-based Cancer Vaccine Potency via Suppression of Interferon-γ-induced Indoleamine 2,3-Dioxygenase Expression.
Noh KT; Son KH; Jung ID; Kang TH; Choi CH; Park YM
J Biol Chem; 2015 May; 290(19):12394-402. PubMed ID: 25814664
[TBL] [Abstract][Full Text] [Related]
3. Ganoderic acid Me induces the apoptosis of competent T cells and increases the proportion of Treg cells through enhancing the expression and activation of indoleamine 2,3-dioxygenase in mouse lewis lung cancer cells.
Que Z; Zou F; Zhang A; Zheng Y; Bi L; Zhong J; Tian J; Liu J
Int Immunopharmacol; 2014 Nov; 23(1):192-204. PubMed ID: 25138378
[TBL] [Abstract][Full Text] [Related]
4. Sodium butyrate inhibits interferon-gamma induced indoleamine 2,3-dioxygenase expression via STAT1 in nasopharyngeal carcinoma cells.
He YW; Wang HS; Zeng J; Fang X; Chen HY; Du J; Yang XY
Life Sci; 2013 Oct; 93(15):509-15. PubMed ID: 23942267
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase, an immunomodulatory protein, is suppressed by (-)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells.
Cheng CW; Shieh PC; Lin YC; Chen YJ; Lin YH; Kuo DH; Liu JY; Kao JY; Kao MC; Way TD
J Agric Food Chem; 2010 Jan; 58(2):887-94. PubMed ID: 19928918
[TBL] [Abstract][Full Text] [Related]
6. Indoleamine 2,3-Dioxygenase Activity During Acute Toxoplasmosis and the Suppressed T Cell Proliferation in Mice.
Ufermann CM; Domröse A; Babel T; Tersteegen A; Cengiz SC; Eller SK; Spekker-Bosker K; Sorg UR; Förster I; Däubener W
Front Cell Infect Microbiol; 2019; 9():184. PubMed ID: 31231617
[No Abstract] [Full Text] [Related]
7. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
Engin AB; Engin A
Adv Exp Med Biol; 2021; 1275():339-356. PubMed ID: 33539022
[TBL] [Abstract][Full Text] [Related]
8. Effects of upregulated indoleamine 2, 3-dioxygenase 1 by interferon γ gene transfer on interferon γ-mediated antitumor activity.
Watcharanurak K; Zang L; Nishikawa M; Yoshinaga K; Yamamoto Y; Takahashi Y; Ando M; Saito K; Watanabe Y; Takakura Y
Gene Ther; 2014 Sep; 21(9):794-801. PubMed ID: 24919418
[TBL] [Abstract][Full Text] [Related]
9. An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells.
Campia I; Buondonno I; Castella B; Rolando B; Kopecka J; Gazzano E; Ghigo D; Riganti C
PLoS One; 2015; 10(5):e0126159. PubMed ID: 25955018
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib Relieves Immune Tolerance in Nasopharyngeal Carcinoma via STAT1 Suppression and Indoleamine 2,3-Dioxygenase Downregulation.
Jiang GM; Wang HS; Du J; Ma WF; Wang H; Qiu Y; Zhang QG; Xu W; Liu HF; Liang JP
Cancer Immunol Res; 2017 Jan; 5(1):42-51. PubMed ID: 27923823
[TBL] [Abstract][Full Text] [Related]
11. p-Coumaric acid inhibits indoleamine 2, 3-dioxygenase expression in murine dendritic cells.
Kim SI; Jeong YI; Jung ID; Lee JS; Lee CM; Yoon MS; Seong EY; Kim JI; Lee JD; Park YM
Int Immunopharmacol; 2007 Jun; 7(6):805-15. PubMed ID: 17466914
[TBL] [Abstract][Full Text] [Related]
12. Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1.
Moretti S; Menicali E; Nucci N; Voce P; Colella R; Melillo RM; Liotti F; Morelli S; Fallarino F; Macchiarulo A; Santoro M; Avenia N; Puxeddu E
J Biol Chem; 2017 Feb; 292(5):1785-1797. PubMed ID: 27994058
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a polysaccharide from the fruiting bodies of Lepista sordida as potent inhibitors of indoleamine 2, 3-dioxygenase (IDO) in HepG2 cells via blocking of STAT1-mediated JAK-PKC-δ signaling pathways.
Luo Q; Yan L; Xu P; Xiong C; Yang Z; Hu P; Hu H; Hong R
Carbohydr Polym; 2018 Oct; 197():540-547. PubMed ID: 30007645
[TBL] [Abstract][Full Text] [Related]
14. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.
Löb S; Königsrainer A; Zieker D; Brücher BL; Rammensee HG; Opelz G; Terness P
Cancer Immunol Immunother; 2009 Jan; 58(1):153-7. PubMed ID: 18418598
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism.
Hanafi LA; Gauchat D; Godin-Ethier J; Possamaï D; Duvignaud JB; Leclerc D; Grandvaux N; Lapointe R
PLoS One; 2014; 9(6):e99211. PubMed ID: 24911872
[TBL] [Abstract][Full Text] [Related]
16. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.
Chen PW; Mellon JK; Mayhew E; Wang S; He YG; Hogan N; Niederkorn JY
Exp Eye Res; 2007 Nov; 85(5):617-25. PubMed ID: 17870068
[TBL] [Abstract][Full Text] [Related]
17. IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.
Put K; Brisse E; Avau A; Imbrechts M; Mitera T; Janssens R; Proost P; Fallarino F; Wouters CH; Matthys P
PLoS One; 2016; 11(2):e0150075. PubMed ID: 26914138
[TBL] [Abstract][Full Text] [Related]
18. Rosmarinic acid inhibits indoleamine 2,3-dioxygenase expression in murine dendritic cells.
Lee HJ; Jeong YI; Lee TH; Jung ID; Lee JS; Lee CM; Kim JI; Joo H; Lee JD; Park YM
Biochem Pharmacol; 2007 May; 73(9):1412-21. PubMed ID: 17229401
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.
Folgiero V; Goffredo BM; Filippini P; Masetti R; Bonanno G; Caruso R; Bertaina V; Mastronuzzi A; Gaspari S; Zecca M; Torelli GF; Testi AM; Pession A; Locatelli F; Rutella S
Oncotarget; 2014 Apr; 5(8):2052-64. PubMed ID: 24903009
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
